Skip to main content
Top

Open Access 18-05-2024 | Type 2 Diabetes

The relationship between low prolactin and type 2 diabetes

Authors: Gie Ken-Dror, David Fluck, Michael E. J. Lean, Felipe F. Casanueva, Thang Sieu Han

Published in: Reviews in Endocrine and Metabolic Disorders

Login to get access

Abstract

Prolactin (PRL) is secreted throughout life in men and women. At elevated levels, its physiological role in pregnancy and lactation, and pathological effects, are well known. However clinical implications of low circulating PRL are not well established. We conducted a meta-analysis to examine the relationship between low PRL levels and type 2 diabetes. Five papers included cross-sectional studies comprising 8,720 men (mean age range 51.4–60 years) and 3,429 women (49.5–61.6 years), and four papers included cohort studies comprising 2,948 men (52.1–60.0 years) and 3,203 women (49.2–60.1 years). Individuals with pregnancy, lactation and hyperprolactinemia, drugs known to alter circulating PRL levels, or pituitary diseases had been excluded. Although most studies used quartiles to categorize PRL groups for analysis, PRL cut-off values (all measured by chemiluminescence immunoassay) were variably defined between studies: the lowest PRL quartiles ranged from 3.6 ng/ml to 7.2 ng/ml in men and between 4.5 ng/ml to 8 ng/ml in women; and the highest PRL quartiles ranged from 6.9 ng/ml to 13 ng/ml in men and 9.6 ng/ml to 15.8 ng/ml in women. Type 2 diabetes was defined variably using self-reported physician’s diagnosis, fasting blood glucose, oral glucose tolerance test or glycated hemoglobin (HbA1C). In cross-sectional studies, compared to individuals in the highest PRL groups (reference), those in the lowest PRL groups had greater risk of type 2 diabetes both in men: odds ratio (OR) and 95% confidence interval = 1.86 (1.56–2.22) and in women: OR = 2.15 (1.63–2.85). In cohort studies, women showed a significant association between low PRL and type 2 diabetes: OR = 1.52 (1.02–2.28) but not men: OR = 1.44 (0.46–4.57). Relatively low heterogeneity was observed (I2 = 25–38.4%) for cross-sectional studies, but higher for cohort studies (I2 = 52.8–79.7%). In conclusion, low PRL is associated with type 2 diabetes, but discrepancy between men and women in the relationship within cohort studies requires further research.
Literature
5.
go back to reference Edinoff AN, Silverblatt NS, Vervaeke HE, et al. Hyperprolactinemia, clinical considerations, and infertility in women on antipsychotic medications. Psychopharmacol Bull. 2021;51(2):131.PubMedPubMedCentral Edinoff AN, Silverblatt NS, Vervaeke HE, et al. Hyperprolactinemia, clinical considerations, and infertility in women on antipsychotic medications. Psychopharmacol Bull. 2021;51(2):131.PubMedPubMedCentral
9.
go back to reference Chahar C, Chahar K, Ankit BS, Gadhwal A, Agrawal RP. Association of serum prolactin level with impaired glucose regulation and diabetes. J Assoc Physicians India. 2017;65(3):34–9.PubMed Chahar C, Chahar K, Ankit BS, Gadhwal A, Agrawal RP. Association of serum prolactin level with impaired glucose regulation and diabetes. J Assoc Physicians India. 2017;65(3):34–9.PubMed
13.
go back to reference Faria de Castro L, Alves Dos Santos Á, Augusto Casulari L, Ansaneli Naves L, Amorim Amato A. Association between variations of physiological prolactin serum levels and the risk of type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2020;166:108247. https://doi.org/10.1016/j.diabres.2020.108247. Faria de Castro L, Alves Dos Santos Á, Augusto Casulari L, Ansaneli Naves L, Amorim Amato A. Association between variations of physiological prolactin serum levels and the risk of type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2020;166:108247. https://​doi.​org/​10.​1016/​j.​diabres.​2020.​108247.
14.
go back to reference Han TS, Antonio L, Bartfai G, et al. Evidence-based definition of hypoprolactinemia in European men aged 40–86 years: the European Male Ageing Study. Rev Endocr Metab Disord. In press. Han TS, Antonio L, Bartfai G, et al. Evidence-based definition of hypoprolactinemia in European men aged 40–86 years: the European Male Ageing Study. Rev Endocr Metab Disord. In press.
16.
go back to reference Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf MI. Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor (s). Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane, 2021. https://training.cochrane.org/handbook/current/chapter-04. Accessed March 2024. Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf MI. Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor (s). Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane, 2021. https://​training.​cochrane.​org/​handbook/​current/​chapter-04. Accessed March 2024.
Metadata
Title
The relationship between low prolactin and type 2 diabetes
Authors
Gie Ken-Dror
David Fluck
Michael E. J. Lean
Felipe F. Casanueva
Thang Sieu Han
Publication date
18-05-2024
Publisher
Springer US
Keyword
Type 2 Diabetes
Published in
Reviews in Endocrine and Metabolic Disorders
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-024-09886-w
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine